Orchestra biomed announces avim therapy-focused satellite symposium at hrs 2025 annual meeting

Fda recently granted breakthrough device designation to avim therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk hrs satellite symposium will feature leading experts in electrophysiology, hypertension management and heart failure presentations will detail clinical results from prior studies demonstrating avim therapy's ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac function symposium will also feature presentation on the backbeat global pivotal study orchestra biomed is currently enrolling in strategic collaboration with medtronic, plc (nyse: mdt) new hope, pa., april 23, 2025 (globe newswire) -- orchestra biomed holdings, inc. (nasdaq: obio, “orchestra biomed” or the “company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an industry-sponsored satellite symposium at the heart rhythm society (“hrs”) 2025 annual meeting, taking place april 24–27, 2025, in san diego, california featuring recent advancements in the company's atrioventricular interval modulation (“avim”) therapy program.
MDT Ratings Summary
MDT Quant Ranking